Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519708 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL3519704 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL30768150 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL21736594 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL21736595 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL4247464 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| Cyclo(Prolylglycyl) SCHEMBL4243772 | 0.94 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL19605682 | 0.93 | KDM4E (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL19605610 | 0.93 | KDM4E (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| US-7304064-B2 | 1-[(indol-3-yl)carbonyl]piperazine derivatives | N.V. ORGANON (NL) | 2007-12-04 | — | — | US | disclosed |
| EP-1549637-B1 | 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES | ORGANON NV (NL) | 2007-05-02 | — | — | EP | disclosed |
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250760-A1 | 1-[(Indol-3-yl)carbonyl]piperazine derivatives | IDO1, OPRL1, OPRK1 | ALDH1A1 689/4885KDM4E 1502/4885MAPT 2304/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | ALDH1A1 985/4885KDM4E 2284/4885MAPT 4508/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | ALDH1A1 1567/4885KDM4E 1719/4885MAPT 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.